Data from Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy

Autor: Toby A. Eyre, John N. Allan, Bruce D. Cheson, Kayla Bigelow, Colleen Dorsey, Andrew D. Zelenetz, Amber C. King, Julie M. Goodfriend, Chadi Nabhan, Hanna B. Weissbrot, Jason C. Lee, Neil Bailey, Erica B. Bhavsar, Talha Munir, Nicolas Martinez-Calle, Christopher P. Fox, Thomas D. Rodgers, Stephen J. Schuster, Timothy J. Voorhees, Kentson Lam, Rachael Pocock, Othman S. Akhtar, Pratik Shah, Krista M. Isaac, Ariel F. Grajales-Cruz, Sirin Khajavian, Andrea Sitlinger, Allison M. Winter, Kate J. Whitaker, Christine A. Garcia, Helen Parry, Craig A. Portell, Paul M. Barr, Joanna Rhodes, Catherine C. Coombs, Michael Choi, Bita Fakhri, Satyen Gohil, John M. Pagel, Jeffrey J. Pu, Pallawi Torka, Alan P. Skarbnik, Jacqueline Barrientos, Javier A. Pinilla-Ibarz, Guilherme Fleury Perini, Maryam Sarraf Yazdy, Chaitra S. Ujjani, Mazyar Shadman, Danielle Brander, Nicole Lamanna, Brian T. Hill, Ryan Jacobs, Lindsey E. Roeker, Anthony R. Mato

Purpose:Venetoclax-based therapy is a standard-of-care option in first-line and relapsed/refractory chronic lymphocytic leukemia (CLL). Patient management following venetoclax discontinuation remains nonstandard and poorly understood.Experimental Des

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e72e05cfed97bbc9e2e47db93b397aae
https://doi.org/10.1158/1078-0432.c.6528851

Supplemental Figure 1 from Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy

Autor: Toby A. Eyre, John N. Allan, Bruce D. Cheson, Kayla Bigelow, Colleen Dorsey, Andrew D. Zelenetz, Amber C. King, Julie M. Goodfriend, Chadi Nabhan, Hanna B. Weissbrot, Jason C. Lee, Neil Bailey, Erica B. Bhavsar, Talha Munir, Nicolas Martinez-Calle, Christopher P. Fox, Thomas D. Rodgers, Stephen J. Schuster, Timothy J. Voorhees, Kentson Lam, Rachael Pocock, Othman S. Akhtar, Pratik Shah, Krista M. Isaac, Ariel F. Grajales-Cruz, Sirin Khajavian, Andrea Sitlinger, Allison M. Winter, Kate J. Whitaker, Christine A. Garcia, Helen Parry, Craig A. Portell, Paul M. Barr, Joanna Rhodes, Catherine C. Coombs, Michael Choi, Bita Fakhri, Satyen Gohil, John M. Pagel, Jeffrey J. Pu, Pallawi Torka, Alan P. Skarbnik, Jacqueline Barrientos, Javier A. Pinilla-Ibarz, Guilherme Fleury Perini, Maryam Sarraf Yazdy, Chaitra S. Ujjani, Mazyar Shadman, Danielle Brander, Nicole Lamanna, Brian T. Hill, Ryan Jacobs, Lindsey E. Roeker, Anthony R. Mato

Supplemental Figure 1: Overall survival of entire cohort from initiation of venetoclax.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48f28a1d557f9e1d57cd60895ef876dc
https://doi.org/10.1158/1078-0432.22474646.v1

Worldwide Examination of Patients with CLL Hospitalized for COVID-19

Autor: Lindsey E Roeker, Lydia Scarfo, Thomas Chatzikonstantinou, Pau Abrisqueta, Toby A. Eyre, Raul Cordoba, Ana Muntañola Prat, Guillermo Villacampa, Lori A. Leslie, Michael Koropsak, Giulia Quaresmini, John N. Allan, Richard R. Furman, Erica B Bhavsar, John M. Pagel, Jose Angel Hernandez-Rivas, Krish Patel, Marina Motta, Neil Bailey, Fatima Miras, Nicole Lamanna, Rosalia Alonso, Santiago Osorio-Prendes, Candida Vitale, Manali Kamdar, Patricia Baltasar, Anders Österborg, Lotta Hanson, Mónica Baile, Ines Rodríguez-Hernández, Susana Valenciano, Viola Maria Popov, Abelardo Barez Garcia, Ana Alfayate, Ana C Oliveira, Barbara Eichhorst, Francesca M. Quaglia, Gianluigi Reda, Javier Lopez Jimenez, Marzia Varettoni, Monia Marchetti, Pilar Romero, Rosalía Riaza Grau, Talha Munir, Amaya Zabalza, Ann Janssens, Carsten U Niemann, Guilherme Fleury Perini, Julio Delgado, Lucrecia Yanez San Segundo, Ma Isabel Gómez Roncero, Matthew Wilson, Piers Patten, Roberto Marasca, Sunil Iyengar, Amanda Seddon, Ana Torres, Angela Ferrari, Carolina Cuéllar-García, Daniel Wojenski, Dima El-Sharkawi, Gilad Itchaki, Helen Parry, Juan José Mateos-Mazón, Nicolas Martinez-Calle, Shuo Ma, Daniel Naya, Ellen Van Der Spek, Erlene K. Seymour, Eva Gimeno Vázquez, Gian Matteo Rigolin, Francesca Romana Mauro, Harriet S Walter, Jorge Labrador, Lorenzo De Paoli, Luca Laurenti, Elena Ruiz, Mark-David Levin, Martin Šimkovič, Martin Špaček, Rafa Andreu, Renata Walewska, Sonia Perez-Gonzalez, Suchitra Sundaram, Adrian Wiestner, Amalia Cuesta, Angus Broom, Arnon P. Kater, Begoña Muiña, César A Velasquez, Chaitra S. Ujjani, Cristina Seri, Darko Antic, Dominique Bron, Elisabeth Vandenberghe, Elise A. Chong, Enrico Lista, Fiz Campoy García, Giovanni Del Poeta, Inhye Ahn, Jeffrey J. Pu, Jennifer R Brown, Juan Alfonso Soler Campos, Lara Malerba, Livio Trentin, Lorella Orsucci, Lucia Farina, Lucia Villalon, Maria Jesus Vidal, Maria Jose Sanchez, Maria Jose Terol, Maria Rosaria De Paolis, Massimo Gentile, Matthew S. Davids, Mazyar Shadman, Mohamed A Yassin, Myriam Foglietta, Ozren Jaksic, Paolo Sportoletti, Paul M. Barr, Rafael Ramos, Raquel Santiago, Rosa Ruchlemer, Sabina Kersting, Scott F. Huntington, Tobias Herold, Yair Herishanu, Meghan C. Thompson, Sonia Lebowitz, Christine Ryan, Ryan W. Jacobs, Craig A. Portell, Krista Isaac, Alessandro Rambaldi, Chadi Nabhan, Danielle M. Brander, Emili Montserrat, Giuseppe Rossi, Jose A. Garcia-Marco, Marta Coscia, Nikita Malakhov, Noemi Fernandez-Escalada, Sigrid Strand Skånland, Callie C. Coombs, Paola Ghione, Stephen J. Schuster, Robin Foà, Antonio Cuneo, Francesc Bosch, Kostas Stamatopoulos, Paolo Ghia, Anthony R. Mato, Meera Patel

Publikováno v: Blood

Introduction: Patients (pts) with CLL may be at particular risk of severe COVID-19 given advanced age and immune dysregulation. Two large series with limited follow-up have reported outcomes for pts with CLL and COVID-19 (Scarfò, et al. Leukemia 202

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ba23eadf6f92b53da22c9de45c8d148
https://doi.org/10.1182/blood-2020-136408

Single-Cell Multi-Omics Reveals Distinct Paths to Survival of Admixed BTKC481 Mutant Vs. Wild-Type Cells in Clinically Progressing Chronic Lymphocytic Leukemia

Autor: Federico Gaiti, Rafael C. Schulman, Chelston Ang, Ronan Chaligne, Adrian Wiestner, Nathaniel D. Omans, Anna S. Nam, Danny Luan, Richard R. Furman, Preeti Trisal, Gregory Mullokandov, Neville Dusaj, Joshua S. Schiffman, Erica B. Bhavsar, Franco Izzo, Andrew Lipsky, Shirley Chen, Anita Gandhi, Kyu-Tae Kim, Dan A. Landau, Chingiz Underbayev, Paulina Chamely, John N. Allan

Publikováno v: Blood. 136:40-42

Mutations in the kinase binding domain of BTK at position C481 are associated with resistance to BTK inhibitor (BTKi) therapy in chronic lymphocytic leukemia (CLL). Nearly half of patients manifesting clinical progression with these alterations exhib

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8c9dd049c93c3f6d9ac317723741d34a
https://doi.org/10.1182/blood-2020-138374

Outcomes in CLL patients with NOTCH1 regulatory pathway mutations

Autor: Richard R. Furman, Ghaith Abu-Zeinah, Erica B. Bhavsar, John N. Allan, Daniel R. Helbig, Paul J. Christos

Publikováno v: American Journal of Hematology. 96

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70754237f78521178df70c8561e031db
https://doi.org/10.1002/ajh.26140